A Phase I/II study of Selinexor (SEL) with Sorafenib in Patients with Relapsed and/or Refractory FLT3- mutated Acute Myeloid Leukemia (AML)A Phase I/II study of Selinexor (SEL) with Sorafenib in Patients with Relapsed and/or Refractory FLT3- mutated Acute Myeloid Leukemia (AML) Learn More